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Summary: Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 are simply-deter-
mined screening analytes if growth hormone deficiency is suspected. The analysis of growth hormone secretion
using standardised stimulation tests and secretion profiles is complicated and expensive in comparison. In retrospect,
we have examined the value of insulin-like growth factor-I and its binding protein-3 for the diagnostic clarification
of patients with short stature (n = 117). In 39/117 patients growth hormone secretion was investigated as ward
patients. Growth hormone deficiency was diagnosed in 10 patients, for 16 patients the diagnosis was neurosecretory
dysfunction. For all patients (n = 7) with lowered insulin-like growth factor binding protein-3 and insulin-like
growth factor-I values (insulin-like growth factor binding protein-3 < 5th percentile, insulin-like growth factor-I
< 10th percentile) a growth hormone disorder was proven. Conversely, however, only 3/10 patients with classical
growth hormone deficiency (n = 3) showed a lowering of both analytes. 8/10 patients with classical growth hor-
mone deficiency and 8/16 patients with neurosecretory dysfunction had at least one lowered value. Two patients
showed normal values for insulin-like growth factor-I and insulin-like growth factor binding protein-3 despite
biochemically proven growth hormone deficiency. The combined determination of insulin-like growth factor-I and
insulin-like growth factor binding protein-3 can provide valuable help during preliminary diagnosis of patients of
short stature, indicating a disturbance of the growth hormone secretion if the values are lowered. Normal values do
not, however, exclude the possibility of a growth hormone deficiency. Inpatient endocrinological testing is indispen-
sible if growth hormone deficiency is suspected.
Introduction
Growth hormone deficiency as the cause of short stature
is relatively rare compared to normal variant short stat-
ure, such as familial short stature or constitutional delay
of growth and puberty. Investigations of the hypothala-
mic-pituitary growth hormone axis are difficult and ex-
pensive in time and money.
Simple and reliable screening tests of growth hormone
secretion are desirable for diagnosis of growth hormone
deficiency. Insulin-like growth factor-I and its most im-
portant binding protein in serum, insulin-like growth
factor binding protein-3 are possible candidates (1,2).
Insulin-like growth factor-I is a polypeptide consisting
of 70 amino acids, with a relative molecular mass of
Mr = 7649 (3). The serum concentration of insulin-like
growth factor-I is primarily determined by the amount
of growth hormone produced (4, 5); in addition, the liver
as main site of synthesis of insulin-like growth factor-I
(6, 7), and nutrition (8, 9, 10) plays an important role.
') Parts of this publication were presented at the 90. Anniversary
of the German Society of Pediatrics in Hannover 1994.
The concentrations of insulin-like growth factor-I in se-
rum are dependent on gender and age, or sexual devel-
opment (11). Insulin-like growth factor-I shows only
slight daily variations (12) due to the almost complete
binding to carrier proteins, and has an effective half-life
of about 12-18 hours (5, 13, 14).
Insulin-like growth factor binding protein-3 is the most
important binding protein for insulin-like growth factor-
I in serum (15, 16). It shares the most important charac-
teristics with insulin-like growth factor-I: Regulation by
growth hormone (17), important role of liver physiology
and nutrition (18, 19). Concentrations in serum are af-
fected by kidney function (20) and are age-dependent
(21, 22), daily variations are practically absent (13, 23).
Therefore, both analytes fulfil important preconditions:
1. The production is directly dependent on growth hor-
mone (4, 17, 22, 24).
2. The determination is independent of the time of day
due to the long metabolic half-life (insulin-like growth
factor binding protein-3: range of days (13, 22, 23); in-
sulin-like growth factor-I: almost a day (7, 9, 10)), and
negligible circadian fluctuations (22, 23, 25).
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3. Commercial tests are available.
We have examined retrospectively the value of serum
insulin-like growth factor-I and insulin-like growth
factor binding protein-3 determinations in the diagnosis
of growth hormone deficiency.
Positive predictive value (= probability of disease for a patient
with a pathological test result): correct positive test/total of posi-
tive tests.
Negative predictive value (= probability of exclusion of disease
for a patient with a normal test result): correct negative test/total
of negative tests.
Patients and Methods
Insulin-like growth factor-I and its binding protein-3 were deter-
mined for 117 patients with short stature (standing height ^ 3rd
percentile according to Swiss standards (26)) at the first visit in
our outpatient clinic (from February 1993 —September 1994). In
retrospect, the initial insulin-like growth factor-I and insulin-like
growth factor binding protein-3 values were compared with the
later diagnoses, in order to ascertain the applicability of these ana-
lytes for the diagnosis of growth hormone deficiency in these pa-
tients.
Growth hormone secretion was evaluated in 39/117 patients (31
males, 8 females, growth rate < 10th percentile according to Swiss
standards (26)) using 2 pharmacological stimulation tests and an
overnight secretion profile. None of the 39 patients had concomi-
tant chronic diseases, karyotype was normal in all girls. The age
of the children at first examination was between 3.6 and 14.3 years,
the weight for height index (calculated on normal values according
to Swiss standards (26)) was between 87% and 118% (min.-
max.). Bone age was retarded in all patients with growth hormone
deficiency and neurosecretory dysfunction (1.9 ± 1.3 years, mean
± standard deviation). Growth hormone therapy was started with
a dose of 0.5 lU/kg body weight/week (daily s. c. injections) in
all patients with growth hormone deficiency and neurosecretory
dysfunction. Mean height velocity increased significantly in the
first year of growth hormone therapy from 2.6 ± 0.9 cm/year (pre-
treatment) to 8.8 ± 1.6 cm/year in the patients with growth hor-
mone deficiency and from 3.9 ± 1.1 cm/year to 7.7 ± 1.4 cm/year
in the patients with neurosecretory dysfunction.
Two growth hormone stimulation tests were performed (insulin-
induced hypoglycaemia and/or arginine test and/or clonidine test)
according to standard methods (27). The interval of time between
blood sampling for serum insulin-like growth factor-I/insulin-like
growth factor binding protein-3 and growth hormone standard sti-
mulation tests was 2 — 8 months. Growth hormone deficiency was
diagnosed if no peak growth hormone level > 10 μg/l could be
measured in either test. Growth hormone secretion profile: blood
samples were taken every 20 min (from 8 p. m. to 6 a. m.) using
an indwelling venous catheter. The evaluation was carried out
using the Pulsar programme of Merriam and W chter (28). Refer-
ence values of our laboratory: area above baseline 120 ± 22.6 μg/l
(mean ± standard deviation), mean growth hormone concentration
> 3 μ§/1. The diagnosis neurosecretory dysfunction was made if
the growth hormone profile was pathological and growth hormone
increased > 10 μg/l in at least one of the stimulation tests.
Insulin-like growth factor-I was determined after acid-alcohol ex-
traction using a commercial radioimmunoassay (Serono, Freiburg,
Germany). The insulin-like growth factor-I level was defined to be
low if the value was less than the lower standard value (= < 10
percentile). Table 1 shows the standard values given by the manu-
facturer.
Insulin-like growth factor binding protein-3 was determined using
a commercial radioimmunoassay (Mediagnost, T bingen, Ger-
many). Insulin-like growth factor binding protein-3 levels less than
the 5th percentile were defined to be low. Table 2 shows the refer-
ence values (5th—95th percentile).
Defini t ions
Sensitivity: correct positive test/number of patients affected.
Specificity: correct negative test/number of patients non-affected.
Results
In 78/117 patients, normal variant short stature was
diagnosed due to clinical and auxological data. Growth
hormone secretion was not tested in these patients. Insu-
lin-like growth factor-I and insulin-like growth factor
binding protein-3 concentrations were either both nor-
mal (n = 47/78), or one value was decreased (n = 31/
78): low insulin-like growth factor-I in 17/31 patients,
low insulin-like growth factor binding protein-3 in 14/
31 patients. Over a follow-up period of two years, there
was no doubt about the diagnosis of normal variant
short stature.
In 39/117 patients, growth hormone deficiency was sus-
pected due to clinical data and growth hormone secre-
tion was tested. The investigations showed growth hor-
mone deficiency in 10 patients, neurosecretory dysfunc-
tion in 16 patients, and normal variant short stature in
13 patients. Insulin-like growth factor-I and insulin-like
growth factor binding protein-3 values of the 39 patients
are shown in figures 1—3.
Patients with growth hormone deficiency
Three of the 10 patients had pathologically low values
for both insulin-like growth factor-I and insulin-like
growth factor binding protein-3. For 5 patients, one low
value and one normal value was measured. Two of the
Tab. 1 Reference values of insulin-like growth factor-I (given by
the manufacturer).
Age (years) Insulin-like growth factor-I
Girls Boys
3-6
6-9
9-12
12-17
36-168
96-264
120-480
240-969
24-144
72-192
72-240
144-672
Tab. 2 Reference values of insulin-like growth factor binding
protein-3 (13).
Age (years) Insulin-like growth factor binding
protein-3 (mg/1)
3-5
5-7
7-9
9-11
11-13
13-15
1.52-3.32
1.66-3.59
1.82-3.80
2.12-4.26
2.22-4.89
2.31-5.24
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10 patients had normal values for both insulin-like
growth factor binding protein-3 (summary of clinical
data see tab. 3). In all, insulin-like growth factor-I was
low for 6/10 patients, insulin-like growth factor binding
protein-3 was low for 5/10 patients.
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Fig. 1 Insulin-like growth factor-I values of 31 male/39 patients
having growth hormone deficiency (·), neurosecretory dysfunction
(D) and normal variant short stature (·). The line represents the
10th percentile for normal children.
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Fig. 2 Insulin-like growth factor-I values of 8 female/39 patients
having growth hormone deficiency (·), neurosecretory dysfunction
(D) and normal variant short stature (·). The line represents the
10th percentile for normal children.
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Fig. 3 Insulin-like growth factor binding protein-3 values of 39
patients having growth hormone deficiency (·), neurosecretory
dysfunction (D) and normal variant short stature (·). The lines
represent the 5th, 50th and 95th percentiles for normal children.
Patients with neurosecretory dysfunction
Four of the 16 patients had low values for both insulin-
like growth factor-I and insulin-like growth factor bind-
ing protein-3. For 4 of the 16 patients, one low value
and one normal value was measured. Half of the patients
had normal values for both insulin-like growth factor-I
and insulin-like growth factor binding protein-3. In all,
7/16 patients had lowered values for insulin-like growth
factor-I and 5/16 lowered values for insulin-like growth
factor binding protein-3.
Patients with normal variant short stature
None of the 13 patients showed pathological values for
both insulin-like growth factor-I and insulin-like growth
factor binding protein-3. Five of 13 patients however,
had one normal and one low value (insulin-like growth
factor-I in 4/13 patients, insulin-like growth factor bind-
ing protein-3 in 1/13 patients).
According to these data (summary see tab. 4), insulin-
like growth factor-I has a sensitivity (specificity) of 60%
(62.1%) as a screening analyte for growth hormone defi-
ciency, or of 50% (69.2%) for a disturbed growth hor-
mone secretion (growth hormone deficiency or neuro-
secretory dysfunction). The positive predictive value of
insulin-like growth factor-I for a disturbed growth hor-
mone secretion is 76.5%, the negative predictive value
is 40.9%. For insulin-like growth factor binding protein-
3 we found a sensitivity (specificity) of 50% (79.3%)
for growth hormone deficiency, or 38.5% (32.3%) for a
disturbed growth hormone secretion. The positive pre-
dictive value of insulin-like growth factor binding pro-
tein-3 for a disturbed growth hormone secretion is
90.9%; the negative predictive value is 42.9%.
The combination of insulin-like growth factor-I and in-
sulin-like growth factor binding protein-3 has a sensitiv-
ity (specificity) of 30% (86.2%) for growth hormone
deficiency and 26.9% (100%) for a disturbed growth
hormone secretion. The positive predictive value of in-
sulin-like growth factor-I and insulin-like growth factor
binding protein-3 for a disturbed growth hormone secre-
tion is 100%, the negative predictive value is 40.6%.
If only one analyte is used, the sensitivity (specificity) is
80% (55.2%) for growth hormone deficiency, and 61.5%
(61.5%) for a disturbed growth hormone secretion. The
positive predictive value for disturbed growth hormone
secretion is 76.2%, the negative predictive value 44.4%
(summary see tab. 5).
Discussion
There is no doubt that the basis for the growth hormone
deficiency diagnosis is auxology. However, in addition
to careful clinical evaluation, simple and reliable labora-
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tory screening tests of growth hormone secretion are de-
sirable. Insulin-like growth factor-I and insulin-like
growth factor binding protein-3 are suggested to be can-
didates for such screening analytes (1,2).
Patients with growth hormone deficiency had, on
average, significantly lower insulin-like growth factor-I
values in serum than healthy controls (4, 11, 12, 29, 30,
31). Serum insulin-like growth factor-I concentrations
increase after growth hormone therapy (32, 33). How-
ever, the use of serum insulin-like growth factor-I values
as a diagnostic test for growth hormone deficiency is
limited by several factors: First of all, the insulin-like
growth factor-I values for healthy children in the first 6
years of life are very low, so that a distinction between
lowered and still normal values is not possible for this
age group (1). Secondly, there is wide scatter of insulin-
like growth factor-I values for healthy controls of the
same age, due to genetic influences (34), so that the
separation between normal and pathological is not
straightforward (1). There have been suggestions in the
literature of anything between the 10th and O.lst percen-
tile for the "cut-off' between normal and pathologic in-
sulin-like growth factor-I concentrations (11, 35, 36).
Because of the almost complete binding of insulin-like
growth factor-I to carrier proteins, it is necessary to pre-
treat the sera (e. g. acid-alcohol extraction) to separate
Tab. 3 Clinical data of two patients with classic growth hormone deficiency and normal insulin-like
growth factor-I/insulin-like growth factor binding protein-3 concentrations.
Patient Sex
(initials)
KM <?
SS ?
Chron.
age
(years)
11.0
11.6
Bone
age
(years)
9.5
10.5
Height
(cm)
136
128
Height
(standard
deviation
score)
-1.43
-2.96
Weight
(kg)
40.4
26.8
Insulin-like
growth
factor-I
(μ§/1)
106
136
Insulin-like
growth
factor
binding
protein-3
(mg/1)
3.1
3.8
Growth
hormone peak
(μ§Ί)
arginine test/
insulin-induced
hypoglycaemia
5.4/3.2
5.3/6.1
Diagnosis
Cranio-
pharyngioma
[diopathic growth
hormone
deficiency
Tab. 4 Retrospective correlation of insulin-like growth factor-I and insulin-like growth factor binding
protein-3 values measured initially, and later diagnosis.
Decreased
Insulin-like growth factor-I
Insulin-like growth factor binding protein-3
Insulin-like growth factor-I or insulin-like
growth factor binding protein-3
Insulin-like growth factor-I and insulin-like
growth factor binding protein-3
Growth hormone
deficiency (n = 10)
6 (60%)
5 (50%)
5 (50%)
3 (30%)
Neurosecretory
dysfunction (n = 16)
7 (36%)
5 (31%)
4 (25%)
4 (25%)
Normal variant short
stature (n = 13)
4(31%)
1 (8%)
5 (38%)
0 (0%)
Reference values:
Insulin-like growth factor-I and insulin-like
growth factor binding protein-3
2 (20%) (50%) (62%)
Tab. 5 Applicability of insulin-like growth factor-I and insulin-like growth factor binding protein-3
for the diagnosis of disorders of growth hormone secretion (classic growth hormone deficiency or
neurosecretory dysfunction).
Sensitivity
Specificity
Positive predictive value
Negative predictive value
Insulin-like
growth factor-I
50%
69.2%
76.5%
40.9%
Insulin-like
growth factor
binding protein-3
38.5%
92.3%
90.9%
42.9%
Insulin-like
growth factor-I
and/or insulin-like
growth factor
binding protein-3
61.5%
61.5%
76.2%
44.4%
Insulin-like
growth factor-I
and insulin-like
growth factor
binding protein-3
26.9%
100%
100%
40.6%
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the insulin-like growth factor-I from the binding protein.
The differing methods of separation cause a marked
variability in values for the many test procedures and
preclude direct comparison of published results.
Our data show a clear overlap of insulin-like growth
factor-I values for patients with growth hormone defi-
ciency, neurosecretory dysfunction and children with
normal growth hormone secretion. Other authors also
reported such overlap. Growth hormone deficiency pa-
tients with normal insulin-like growth factor-I concen-
trations (1, 11, 37, 38), as well as patients with normal
variant short stature and low insulin-like growth factor-
I levels (1, 11, 39, 40, 41) have been reported.
Insulin-like growth factor binding protein-3, the most
important binding protein for insulin-like growth factor-
I in serum (15, 16), shares the most important character-
istics with insulin-like growth factor-I but has one im-
portant advantage compared to insulin-like growth
factor-I: Pre-preparation of samples is not necessary (21,
22). Since normal values for healthy children are rela-
tively high, low values can be easily detected. The use
of insulin-like growth factor binding protein-3 therefore
compares favourably to insulin-like growth factor-I (1).
However, we found that insulin-like growth factor bind-
ing protein-3 was not better than insulin-like growth
factor-I as a marker for a disturbed growth hormone
secretion. Other authors also reported an overlap of insu-
lin-like growth factor binding protein-3 values in chil-
dren with and without growth hormone deficiency. Ci-
anfarani et al. found normal serum insulin-like growth
factor binding protein-3 levels in 50% of their patients
with growth hormone deficiency (36).
For our patients, we found that the single determination
of either insulin-like growth factor-I or insulin-like
growth factor binding protein-3 predict a disturbed
growth hormone secretion in only 50—60% of the pa-
tients with growth hormone deficiency. The prediction
was even lower for patients with neurosecretory dys-
function. In the literature, sensitivity and specificity of
both analytes are generally judged more positively.
However, recent publications found similar results (36).
Because of the relatively small number of patients it
seems questionable to calculate exact percentages for
sensitivity and sensibility, but the data demonstrate, that
the reliability of the two analytes as diagnostic markers
of a disturbed growth hormone secretion is markedly re-
duced.
Growth hormone secretion is not constant (42). Insulin-
like growth factor-I and its binding protein-3 were mea-
sured 2-8 months before growth hormone secretion was
evaluated. This fact may contribute to the low prediction
value of the two analytes. However, the main endoge-
nous factors influencing the pattern of growth hormone
secretion and the response to pharmacological stimula-
tion tests are age and pubertal maturation (43). The
period of time between the two investigations was short
and the majority of the children were still prepubertal.
Therefore, pubertal development should not have influ-
enced the results very much. Another exogenous factor
with influence on growth hormone secretion is psycho-
social distress. However, it is difficult to define psycho-
social distress. In our patients, there was no indication
of psychosocial short stature. Moreover, over a follow-
up period of two years on growth hormone therapy, all
patients with growth hormone deficiency or neurosecre-
tory dysfunction responded to growth hormone with a
significantly increased growth rate. Therefore, we have
no doubt about the diagnosis of disturbed growth hor-
mone secretion in these patients.
The separation of normal and pathological values at the
5th percentile for insulin-like growth factor binding pro-
tein-3 and the 10th percentile for insulin-like growth
factor-I, respectively, is in accordance with the sug-
gested cut-off value of other authors, but is to a certain
extent arbitrary. Growth hormone secretion in a given
population — even in a short statured subpopulation —
is continuous. This raises the general question of estab-
lishing cut-off values. Raising the cut-off value (for ex-
ample, to the 10th percentile for insulin-like growth
factor binding protein-3) would increase the sensitivity
of the analyte, but the increase in sensitivity would of
course be at the cost of specificity. Conversely, a
lowering of the cut-off value (for example, to the 5th
percentile for insulin-like growth factor-I) would effect
an increase of specificity at the cost of sensitivity.
At this point, however, it must be mentioned that the
criteria for the diagnosis of growth hormone deficiency
are to a certain extent arbitrary, too. In early reports, a
peak growth hormone concentration of 5 g/l was em-
ployed to define a normal rise after pharmacological sti-
mulation (45). Later on, the cut-off value increased to
7 g/l and then to 10 g/l (46). A subnormal response
of serum growth hormone concentration to two pharma-
cological stimulation tests is still the widely used
method for diagnosing growth hormone deficiency (46).
This present "gold standard", however, is questioned by
several authors (42, 46), because these non-physiologi-
cal provocative tests have an increased rate of error in
the diagnosis of growth hormone deficiency (35, 44, 47,
48) and a limited reproducibility (42). The measurement
of spontaneous growth hormone secretion gives further
information but is also limited due to variability and re-
duced sensitivity (44, 47, 48). There is no completely
reliable test for diagnosing or excluding growth hor-
mone deficiency (38, 42, 46). Therefore, it is often diffi-
cult to make a clear distinction between normal growth
hormone secretion and growth hormone deficiency.
However, the consequences of the diagnosis and the ex-
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pense of growth hormone therapy still require straight
laboratory diagnostic criteria in addition to a careful
auxological evaluation for diagnosing growth hormone
deficiency (42). Therefore, pharmacological stimulation
tests and spontaneous growth hormone secretion profiles
cannot be abandoned at the present time (42).
Conclusion
The combined measurement of insulin-like growth
factor-I and insulin-like growth factor binding protein-3
produced an abnormal result in 80% of growth hormone
deficiency patients and in 61% of patients with neurose-
cretory dysfunction. Low values for both analytes were
always associated with a disturbed growth hormone
secretion, whereas normal values did not exclude a
growth hormone deficiency. Therefore, we favour the
combined measurement of insulin-like growth factor-I
and insulin-like growth factor binding protein-3 as
screening test for patients with short stature. Despite the
fact that pharmacological stimulation tests have an
increased rate of error in the diagnosis of growth hor-
mone deficiency (35, 44, 47, 48) and their value is ques-
tioned by some authors (46), they are still important in
clinical routine.
If biochemical analytes are considered, we suggest that
the combined assessment of serum insulin-like growth
factor-I and insulin-like growth factor binding protein-3
concentrations is necessary to screen outpatient short stat-
ured children for growth hormone deficiency. Subnormal
values in both tests are highly suggestive of growth hor-
mone deficiency. However, normal values do not exclude
growth hormone deficiency. If auxological and clinical
quantities suggest growth hormone deficiency, a careful
endocrinological investigation is necessary.
Acknowledgements
We wish to thank Mrs Jutta Biskupek-Sigwart and Ms Ulrike Breu-
nig for their expert technical assistance. We thank Mrs Patricia
Schmidt for linguistic editing the manuscript.
References
1. Blum WF. Insulin-like growth factors and their binding pro-
teins. In: Ranke MB, editor. Functional endocrinologic diag-
nostics in children and adolescents. Mannheim: J&J Verlag,
1993:102-17.
2. Tassoni P, Cacciari E, Cau M, Colli C, Tosi M, Zucchini S, et
al. Variability of growth hormone response to pharmacological
and sleep tests performed twice in short children. J Clin En-
docrinol Metab 1990; 71:230-4.
3. Rinderknecht E, Humbel RE. The amino acid sequence of hu-
man insulin-like growth factor-I and its structural homology
with proinsulin. J Biol Chem 1978; 253:2769-76.
4. Furlanetto RW, Underwood LE, Van Wyk JJ, D'Ercole AJ.
Estimation of somatomedin-C levels in normals and patients
with pituitary disease by radioimmunoassay. J Clin Invest
1977; 60:648-57.
5. Zapf J, Kiefer M, Merryweather J, Masiarz F, Bauer D, Born
W, et al. Isolation from adult human serum of four insulin-like
growth factor (IGF) binding proteins and molecular cloning of
one of them that is increased by IGF I administration and in
extrapancreatic tumor hypoglycemia. J Biol Chem 1990;
265:4892-8.
6. Roberts CT, Brown AL, Graham DE, Seelig S, Berry S, Gab-
bay KH, et al. Growth hormone regulates the abundance of
insulin-like growth factor-I RNA in adult rat liver. J Biol Chem
1986; 261:10025-8.
7. Schwander JC, Hauri C, Hapf J, Froesch ER. Synthesis and
secretion of insulin-like growth factor and its binding protein
by the perfused rat liver: dependence on growth hormone
status. Endocrinology 1983; 113:297-305.
8. Emler CA, Schalch DS. Nutritionally-induced changes in he-
patic insulin-like growth factor-I (IGF-I) gene expression in
rats. Endocrinology 1987; 120:832-4.
9. Hintz RL, Suskind R, Amatayakul K, Thanangkul O, Olson R.
Plasma somatomedin and growth hormone values in children
with protein-calorie malnutrition. J Pediatr 1978; 92:153-6.
10. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regu-
lation of the insulin-like growth factors. Endocrine Reviews
1994; 16:80-101.
11. Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL. Insulin-like
growth factors I and II in evaluation of growth retardation. J
Pediatr 1986; 109:428-33.
12. Dean HJ, Kellet JG, Bala RM, Guyda HJ, Bhaumick B, Posner
BI, et al. The effect of growth hormone treatment on soma-
tomedin levels in growth hormone-deficient children. J Clin
Endocrinol Metab 1982; 55:1167-73.
13. Bacter RC, Cowell CT. Diurnal rhythm of growth hormone-
independent binding protein for the insulin-like growth factors
in human plasma. J Clin Endocrinol Metab 1987; 65:432-40.
14. Guier HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth
factors I and II in healthy man. Estimations of half-lives and
production rates. Acta Endocrinol Copenh 1989; 121:753-8.
15. Baxter RC, Marin JL. Structure of the Mr 140,000 growth hor-
mone-dependent insulin-like growth factor binding protein
complex: determination by reconstitution and affinity-labeling.
Proc Natl Acad Sei USA 1989; 86:6898-902.
16. Martin JL, Baxter RC. Insulin-like growth factor binding pro-
tein from human plasma: purification and characterization. J
Biol Chem 1987; 261:8754-60.
17. Blum WF, Albertson-Wikland K, Rosberg S, Ranke MB. Se-
rum levels of insulin-like growth factor (IGF) and IGF-binding
protein 3 (IGFBP-3) reflect spontaneous growth hormone
secretion. J Clin Endocrinol Metab 1993; 76:1610-6.
18. Albiston AL, Herington AC. Tissue distribution and regulation
of the insulin-like growth factor (IGFP)-binding protein-3
messenger ribonucleic acid (mRNA) in the rat: comparison
with the IGF-I mRNA expression. Endocrinology 1992;
130:497-502.
19. Ranke MB, Blum WF, Frisch H. The acid-stable subunit of
insulin-like growth factor binding protein (IGFBP-3) in disor-
ders of growth. In: Drop SLS, Hintz RL, editors. Insulin-like
growth factor binding proteins. Amsterdam: Excerpta Medica,
1989:103-13.
20. Blum WF, Ranke MB, Kietzmann K, Tönshoff B, Mehls O.
Growth hormone resistance and inhibition of somatomedin ac-
tivity by excess of the insulin-like growth factor binding pro-
tein in uremia. Pediatr Nephrol 1991; 5:539-44.
21. Baxter RC, Martin JL. Radioimmunoassay of growth hor-
mone-dependent insulin-like growth factor binding protein in
human plasma. J Clin Invest 1986; 78:1504-12.
22. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ,
Bierich JR. A specific radioimmunoassay for the growth hor-
mone (GH)-dependent somatomedin-binding protein and its
use for diagnosis of the GH deficiency. J Clin Endocrinol
Metab 1990; 70:1292-8.
23. Jorgensen JOL, Blum WF, Moller N, Ranke MB, Christiansen
JS. Circadian patterns of the serum insulin-like growth factors
Koch and Dörr: Screening for growth hormone deficiency 385
(IGF) II and IGF binding protein 3 in growth hormone defi-
cient patients and age- and sex-matched normal subjects. Acat
Endocrinol Copenh 1990; 123:257-62.
24. Zapf J, Walter H, Froesch ER. Radioummunological determi-
nation of insulin-like growth factors I and II in normal subjects
and in patients with growth disorders and extrapancreatic tu-
mor hypoglycemia. J Clin Invest 1981; 68:1321-30.
25. Minuto JP, Underwood LE, Grimaldi P, Furlanetto RW, Van
Wyk JJ, Giordano G. Decreased serum somatomedin C con-
centration during sleep: temporal relationship to the nocturnal
surges of growth hormone and prolactin. J Clin Endocrinol
Metab 1981; 52:399-403.
26. Prader A, Largo RH, Molinari L, Issler C. Physical growth
of Swiss children from birth to 20 years of age. First Zurich
longitudinal study of growth and development. Helv Paediatr
Acta 1989; 52 Suppl: 1-125.
27. Hauffa BP. Klinische und laboranalytische Meßwerte. In: Sto-
lecke H, editor. Endokrinologie des Kindes- und Jugendalters.
Berlin: Springer-Verlag, 1992:784-7.
28. Merriam GR, Wächter KW. Algorithms for the study of epi-
sodic hormone secretion. Am J Physiol 1982; 243:310—8.
29. D'Ercole AJ, Underwood LE, Van-Wyk JJ. Serum soma-
tomedin-C in hypopituitarism and in other disorders of growth.
JPediatr 1977; 90:375-81.
30. Ranke MB, Blum WF, Bierich JR. Clinical relevance of serum
measurements of insulin-like growth factors and somatomedin
binding proteins. Acta Pediatr Scand 1988; 347 Suppl: 114-26.
31. Zapf J, Rinderknecht E, Humbel RE, Froesch ER. Nonsupres-
sible insulin-like activity (NSILA) from human serum: recent
accomplishments and their physiologic implications. Metab
ClinExp 1978; 27:1803-23.
32. Copeland KC, Underwood LE, Van Wyk JJ. Induction of im-
munoreactive somatomedin-C in human serum by growth hor-
mone: dose response relationships and effect on Chromato-
graphie profiles. J Clin Endocrinol Metab 1980; 50:690-7.
33. Rosenfeld RG, Kemp SF, Hintz RL. Constancy of soma-
tomedin response to growth hormon treatment of hypopituitary
dwarfism and lack of correlation with growth rate. J Clin En-
docrinol Metab 1981; 53:611-7.
34. Kao PC, Metheny AP, Lang CA. Insulin-like growth factor-I
comparisons in healthy twin children. J Clin Endocrinol Metab
1994; 78:310-2.
35. Blum WF. Die Bedeutung von IGF-I, IGF-II und IGFBP-3 für
die Diagnostik des Wachstumshormonmangels. In: Ranke MB,
Stolecke H, editors. Diagnostik des Wachstumshormonman-
gels. Ankum: Verlag Dokument und Bild, 1994:197-233.
36. Cianfarani S, Boemi S, Spagnoli A, Cappa M, Argiro G, Vac-
caro F, et al. Is IGF binding protein-3 assessment helpful for
the diagnosis of growth hormone deficiency? Clin Endocrinol
1995; 43:43-7.
37. Adan L, Souberbielle JC, Brauner R. Diagnostic markers of
permanent idiopathic growth hormone deficiency. J Clin En-
docrinol Metab 1994; 78:353-8.
38. Smith WJ, Nam TJ, Underwood LE, Bubsy WH, Celnicker A,
Clemmons DR. Use of insulin-like growth factor binding pro-
tein 2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth
hormone status in short children. J Clin Endocrinol Metab
1993; 77:1264-99.
39. Binoux M, Gourmelen M, Girard F. Serum levels of insulin-
like growth factor (IGF) and IGF-binding protein in constitu-
tionally short children and adolescents. Acta Endocrinol Co-
penh 1986; 113:145-52.
40. Cacciari E, Cicognani A, Pirazzoli P, Tassoni P, Salardi S, Ca-
pelli M, et al. Differences in somatomedin-C between short-
normal subjects and those of normal height. J Pediatr 1985;
106:891-4.
41. Rudman D, Kutner MH, Chawla RK. The short child with sub-
normal plasma somatomedin C. Pediatr Res 1985; 19:975 — 80.
42. Cacciari EC, Tassoni P, Cicognani A, Pirazzoli P, Salardi S,
Balsamo A, et al. Value and limits of pharmacological and
physiological tests to diagnose growth hormone (GH) defi-
ciency and predict therapy response: first and second retesting
during replacement therapy of patients defined as GH defi-
cient. J Clin Endocrinol Metab 1994; 79:1663-9.
43. Martha PM Jr, Gorman KM, Blizzard RM, Rogol AD, Veld-
huis JD. Endogenous growth hormone secretion and clearance
rates in normal boys as determined by deconvolution analysis:
relationship to age, pubertal status, and body mass. J Clin En-
docrinol Metab 1992; 74:336-44.
44. Rocchiccioli P, Pienkowski C, Tauber MT, Uboldi F, Enjaume
C. Association of pharmacological test and study of 24-hour
growth hormone secretion in the investigation of growth retar-
dation in children: analysis of 257 cases. Horm Res 1991;
35:70-5.
45. Kaplan SL, Abrams CAL, Bell JJ, Conte FA, Grumbach MM.
Growth and growth hormone. I. Changes in serum level of
growth hormone following hypoglycemia in 134 children with
growth retardation. Pediatr Res 1968; 2:43-63.
46. Rosenfeld RG, Albertson-Wikland K, Cassorla F, Frasier SD,
Hasegawa Y, Hintz RL, et al. The diagnosis of childhood
growth hormone deficiency revisited. J Clin Endocrinol Metab
1995; 80:1532-40.
47. Donaldson DL, Hollowell JG, Pan F, Gifford RA, Moore WV.
Growth hormone secretory profiles: variation on consecutive
nights. J Pediatr 1989; 115:51-6.
48. Donaldson DL, Pan F, Hollowell JG, Stevenson JL, Gifford
RA, Moore WV. Reliability of stimulated and spontaneous
growth hormone (GH) levels for identifying the child with low
GH secretion. J Clin Endocrinol Metab 1991; 72:647-52.
Received June 13'/November 12, 1996/February 24, 1997
Corresponding author: Dr. Andreas Koch, Klinik mit Poliklinik
für Kinder und Jugendliche, Friedrich-Alexander-Universität
Erlangen-Nümberg, Loschgestraße 15, D-91054 Erlangen,
Germany

